Pitch presentation by P1vital at ECO14 in Preston.

1. www.p1vitalproducts.com 1

2. www.p1vitalproducts.com
What’s the problem?
Depression is the number one cause of disability in the world
(WHO – 2017)
Mental health and behavioural conditions Account for 31% of all fit notes
(NHS digital 2017)
Cost to government inc NHS £24 - £27 billion
Cost to employers (absenteeism /
presenteeism)
£33 - £42 billion
# antidepressants dispensed in 2016 64.7 million (doubling over last decade)
# people per year to receive antidepressant
therapy for 1st time and/or recurring episode
800,000
# patients who will not respond to 1st
treatment they are given
~50%; each treatment cycle takes 4-6
weeks to detect response
Reoccurrence of depression 50% after 1st; 70% after 2nd; 90% after 3rd
2

3. www.p1vitalproducts.com
What’s the solution?
 Holistic approach to the management of depression is required
 Better understanding of the disease, its treatment and prevention
 Awareness of the triggers and risk factors for depression
 Social withdrawal as an early indicator on coming depressive episode
 Preventing re-occurrence
 Reducing suicide
 Leverage our understanding of how treatments for depression work
 Negative emotional bias as a precursor of oncoming mood
3

4. www.p1vitalproducts.com
HAPPY
ANGRY CONTEMPT DISGUST SADNESS
FEAR SURPRISE
The PReDicT Test works by measuring subtle changes in the way patients
interpret emotional information through their recognition of facial expressions

5. www.p1vitalproducts.com
P1vital® PReDicT Test
Improves treatment of depression
 Quickly detects if treatment is not
working
 Monitors patient symptoms
 Assesses symptom severity
 Multi-platform, easy to use
 marked medical device
 Improves clinical decision making
 Reduces GP practice visits
 Accelerates patient recovery via
medicines optimisation
 Reduces side effects associated
with inappropriate prescribing
 Reduce healthcare costs
5
FEATURES BENEFITS
www.p1vitalproducts.com

6. www.p1vitalproducts.com
EU Horizon 2020 SME award
Phase 2 award - €4M for PReDicT
http://predictproject.p1vitalproducts.com/
 PReDicT study ongoing across 5 EU
countries including UK, with results
due out early 2019
 PReDicT Test so far deployed in:
 24 GP surgeries in England;
completed by 323 depressed
patients
 32 clinical practices across
mainland Europe; completed by
173 depressed patients
 Preliminary UK data (N=217)
shows:
 After 8w, more people responding
to antidepressant treatment:
PReDicT 67% vs TaU 51%
 GPs willing to change medications
on reviewing PReDicT data
 Patient engagement is high
6
Patients prescribed
antidepressant
No response
Switch antidepressant
No response
Increase dose
Week 0
Week 4-6
Week 8-12
Week 0
PReDicT
Week 1
PReDicT
Week 2
PReDicT
TaU PReDicT
Reduce 8–12 week cycle to a 2 week cycle

7. www.p1vitalproducts.com
Working together to provide a holistic solution
for patients living with depression
 With NHS, wish to optimise real world implementation of the PReDicT Test
to enable its wider deployment across UK primary care to determine real
healthcare benefits
 Looking for early adopters:
 CCG engagement to demonstrate the business case for adoption
 GP partnerships for participation in implementation studies
 Ideal: PPL collaboration with NHS, DWP/W&H programme & Employer to
demonstrate value proposition of the PReDicT Test to better manage
depression
7
Poor
health/well
being
Good
health/
well being
Family
History of
depression
PReDicT
Digital
assessments
PReDicT
Antidepressants
IAPT
PReDicT
Monitoring and
alerts
PReDicT
TRD
PReDicT Suicide
Alerts
Healthy At Risk
Acute
Intervention Continuation and risk of relapse Suicide risk
Employer and W&H NHS and W&H